At a glance: key differences
- Mechanism: Cagrilintide is a long‑acting amylin analogue acting at amylin (calcitonin) receptors to enhance satiety and slow gastric emptying. Semaglutide is a GLP‑1 receptor agonist that reduces appetite, slows gastric emptying and improves glycaemic control.
- Evidence: Semaglutide has extensive phase 3 data and approved brands (Ozempic/Wegovy). Cagrilintide is investigational; early studies show appetite and weight effects, with the combination of cagrilintide + semaglutide (often called CagriSema) showing promising results.
- Availability in Australia: Semaglutide is prescription‑only and available (supply can vary). Cagrilintide is not TGA‑approved; access is usually limited to clinical trials.
- Side effects: Both commonly cause gastrointestinal symptoms (nausea, vomiting, fullness). Semaglutide has established class warnings (for example thyroid C‑cell tumour risk in rodents, pancreatitis warnings); long‑term safety for cagrilintide is still being defined.
How they work: appetite and satiety pathways
While both agents reduce energy intake, they act through different receptors in the brain–gut axis.
- Cagrilintide (amylin analogue): Mimics the satiety hormone amylin, acting on amylin receptor complexes (CTR/RAMP) in regions like the area postrema. Typical effects include reduced meal size, fewer snacks and slower gastric emptying, which together increase fullness.
- Semaglutide (GLP‑1 receptor agonist): Activates central and peripheral GLP‑1 receptors to suppress appetite, delay gastric emptying and improve post‑meal insulin responses and glycaemia. Many users report earlier satiety and reduced cravings.
Because these pathways are distinct, researchers are studying a combined approach (cagrilintide + semaglutide). Early data suggest additive effects on weight loss, but this combination remains investigational.
Weight loss evidence: what trials suggest
Semaglutide
- In people with overweight or obesity without diabetes, weekly semaglutide at weight‑management doses (Wegovy) produced around 10–15% average weight loss over ~68 weeks in large phase 3 trials.
- In type 2 diabetes, weight reduction is typically lower on average than in non‑diabetes cohorts, but still clinically meaningful.
Cagrilintide
- Monotherapy: Early‑stage studies indicate meaningful appetite reduction and weight loss over several months; effect sizes vary by dose and study design.
- Combination with semaglutide (CagriSema): Investigational data suggest greater weight loss than semaglutide alone at comparable time points, though longer‑term outcomes and safety are still being evaluated.
Bottom line: semaglutide has robust, regulatory‑grade evidence and approved use; cagrilintide (and cagrilintide + semaglutide) look promising but remain in clinical development.
What the appetite experience can feel like
- Semaglutide: Earlier satiety, reduced cravings and smaller portions; some users experience nausea or food aversions during titration.
- Cagrilintide: Strong satiety signalling with smaller meal sizes and reduced snacking; GI effects are still common in studies.
- Together (investigational): Additive satiety effects are being explored; tolerability varies and requires careful dose escalation in trials.
Side effects and safety considerations
- Common to both: Nausea, vomiting, diarrhoea/constipation, abdominal discomfort, early fullness. Usually most noticeable during dose escalation.
- Semaglutide class warnings: Includes risk of gallbladder disease, rare pancreatitis, and a boxed warning in some regions about thyroid C‑cell tumours seen in rodents (relevance to humans is uncertain). Not for pregnancy or certain endocrine conditions. Review product information and speak with a doctor.
- Cagrilintide: Long‑term safety continues to be defined; similar GI profile is common in trials. As an investigational agent, prescribing information is not finalised.
Medical review is essential, especially if you have a history of pancreatitis, gallbladder disease, severe GI disease, medullary thyroid carcinoma, MEN2 or are pregnant/breastfeeding.
Dosing and administration
- Semaglutide: Once‑weekly subcutaneous injection. For weight management, doses are titrated over weeks to a target maintenance dose (for example up to 2.4 mg with Wegovy). For diabetes (Ozempic), approved doses differ.
- Cagrilintide: Studied as a once‑weekly subcutaneous injection with dose levels evaluated in trials. No approved dosing in Australia at this time.
Availability and legality in Australia
- Semaglutide: Prescription‑only. Approved brands include Ozempic (type 2 diabetes) and Wegovy (weight management). Supply and pharmacy availability can vary. See: Buy Semaglutide Australia, Semaglutide Cost Australia, Semaglutide Prescription Australia, Is Semaglutide Legal in Australia?.
- Cagrilintide: Not TGA‑approved as a medicine at this time. Access is generally limited to clinical trials or research settings. Be cautious of online or grey‑market products. Learn more: What Is Cagrilintide?, Is Cagrilintide Legal in Australia?, Buy Cagrilintide Australia.
Which might suit you?
- Choose semaglutide if you want an approved, guideline‑supported option with extensive evidence for weight loss and/or type 2 diabetes management, and you can access and tolerate it.
- Consider trials if you’re interested in investigational approaches like cagrilintide or the cagrilintide + semaglutide combination under study. Clinical trial participation involves strict eligibility and monitoring.
- Co‑morbidities: For people with type 2 diabetes, semaglutide’s glucose‑lowering effect and cardiometabolic benefits are established. Discuss individual risks and benefits with your doctor.
Frequently asked questions
Which suppresses appetite more: cagrilintide or semaglutide?
Direct head‑to‑head data are limited. Semaglutide is proven to reduce appetite and induce weight loss across large phase 3 programs. Early data suggest cagrilintide reduces meal size and snacking; the investigational combination with semaglutide may deliver greater weight loss than semaglutide alone.
Is cagrilintide stronger than semaglutide?
“Stronger” depends on the outcome measured and dose used. Semaglutide has robust, approved dosing for obesity. Cagrilintide dosing and long‑term efficacy are still being established in trials.
Can you take both together?
A fixed‑dose combination (often called CagriSema) is being researched. Outside trials and regulatory approval, combination use is not standard care.
Are these considered peptides?
Semaglutide is a peptide‑based GLP‑1 analogue. Cagrilintide is an amylin analogue peptide. Their classification as peptides doesn’t change that they are prescription‑only medicines (or investigational) with specific legal rules.
Is cagrilintide available in Australia?
Not as an approved medicine at this time. Access is generally limited to clinical trials. Avoid grey‑market products. See Is Cagrilintide Legal in Australia?.
What kind of weight loss can I expect?
Results vary. Semaglutide trials show around 10–15% average weight loss over ~68 weeks in adults without diabetes. Individual responses differ, and adherence, dose and support all matter.
How do costs compare?
Semaglutide costs depend on brand, dose, supply and clinic fees. Cagrilintide is investigational so standard retail pricing isn’t established. See Semaglutide Cost Australia and Cagrilintide Cost Australia.
Get help comparing cagrilintide vs semaglutide
Send a message and we’ll connect you with information or a suitable Australian provider for regulated, legal options.
Final takeaway
Semaglutide is the current, evidence‑based GLP‑1 option with approved brands in Australia. Cagrilintide targets a complementary satiety pathway and shows promise—especially in combination—but remains investigational. If you’re choosing today, most Australians will consider semaglutide first; if you’re exploring the pipeline, keep an eye on cagrilintide and future combination data.